A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Launched by ASTELLAS PHARMA SINGAPORE PTE. LTD. · Jun 19, 2018

Keywords

ClinConnect Summary

This is an observational registry study and will not provide or recommend any treatment; all decisions regarding treatment are made at the sole discretion of the treating physician in accordance with the treating physician's usual practices and all eligible participants will be enrolled in a certain timeframe. OAB participants enrolled in the study will be categorized into one of two treatment groups, but the study does not plan to compare the two treatment groups.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with OAB symptoms (with or without urgency incontinence) with symptoms for at least three months prior to study enrollment.
• • About to initiate monotherapy of mirabegron or any antimuscarinics therapy for OAB symptoms, prescribed as part of routine clinical practice, which maybe the first course of any treatment for OAB, lapsed of treatment, or switching from one drug to another.
• Exclusion Criteria:
• • Currently receiving more than one medication (including Chinese herbal medicine) for OAB.
• • Current participation in clinical trials of OAB.
• • Have undergone surgery for OAB in the past.
• • Mixed incontinence where stress incontinence is the predominant form.
• • OAB has been treated with onabotulinum toxin A, sacral neuromodulation, percutaneous tibial nerve stimulation, external beam radiation (XRT), stents, surgery, or intermittent catheterization prior to or at time of enrollment.
• • At risk of Acute Urinary Retention (AUR).
• • Neurologic conditions associated with OAB symptoms.
• • Hypersensitivity and contraindication(s) to mirabegron and antimuscarinics.